Neoadjuvant Anastrazole permits higher breast conservation rates

A recently reported trial (Immediate pre-ooperative arimidex compared to tamoxifen trial - IMPACT trial) reported that neoadjuvant anastrazole (an aromatase inhibitor) was more effective than tamoxifen in downsizing breast cancers, that were oestrogen receptor positive, prior to surgery and could be used to downsize tumours that were of borderline size for breast conservation. These data were presented at the 26th San Antonio Breast Cancer Symposium.